Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03428217 · ClinicalTrials.gov registry record · Phase 2
CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma
A Phase 2 study, sponsored by Calithera Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 444
- Enrollment target
NCT03428217 is a Phase 2 study that has completed, run by Calithera Biosciences. The registered enrollment target is 444 participants.
The verdict
NCT03428217, a Phase 2 study, has completed, sponsored by Calithera Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 444 participants
- Enrollment target
Study Summary
Tthe primary objective of this study is to compare blinded Independent Radiology Committee (IRC)-adjudicated progression free survival (PFS) of patients treated with CB-839 + cabozantinib (CB-Cabo) versus placebo + cabozantinib (Pbo-Cabo) for advanced or metastatic clear-cell RCC (ccRCC).
Interventions
- DRUG Placebo
- DRUG Cabozantinib
- DRUG CB-839
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 444 participants |
| Start Date | 2018-04-24 |
| Est. Completion | 2021-07-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03428217
The ClinicalTrials.gov registry entry for NCT03428217 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 444 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Calithera Biosciences, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03428217 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03428217 about?
NCT03428217 is a clinical study titled "CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma". Tthe primary objective of this study is to compare blinded Independent Radiology Committee (IRC)-adjudicated progression free survival (PFS) of patients treated with CB-839 + cabozantinib (CB-Cabo) versus placebo + cabozantinib (Pbo-Cabo) for advanced or metastatic clear-cell RCC (ccRCC).
What is the current status of trial NCT03428217?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 444 participants. The study started on 2018-04-24. Estimated completion is 2021-07-16.
What interventions are being tested in trial NCT03428217?
The interventions under investigation include: Placebo (DRUG), Cabozantinib (DRUG), CB-839 (DRUG).
Who is sponsoring clinical trial NCT03428217?
This trial is sponsored by Calithera Biosciences, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.